NCT00348439

Study to Evaluate Plasmin for the Creation of a Posterior Vitreous Detachment

A Multicenter, Randomized, Double Masked, Placebo Controlled, Sequential Dose Response Study of Intravitreally Administered Plasmin for the Creation of a Posterior Vitreous Detachment (PVD)

• Status: Terminated
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 29 (actual)
• Sponsor: Bausch & Lomb Incorporated · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Plasmin is expected to create a posterior vitreous detachment. The pharmacological creation of a posterior vitreous detachment may be beneficial in a variety of conditions.

Conditions

• Vitreoretinal Traction Syndrome

Interventions

Type	Name	Description
DRUG	Plasmin	27 mg of human-derived plasmin to be reconstituted with 0.9% Sterile Sodium Chloride for a single intravitreal injection.
DRUG	Vehicle	Plasmin formulation, without active ingredient to be reconstituted in 0.9% Sterile Sodium Chloride and administered in a single intravitreal injection.

Timeline

• Start date: 2006-04-01
• Primary completion: 2007-08-01
• Completion: 2007-08-01
• First posted: 2006-07-04
• Last updated: 2019-06-21

Locations

1 site across 1 country: United States